



ASX & MEDIA RELEASE

1 FEBRUARY 2018

MEDLAB PERMITTED TO SELL OR SUPPLY CANNABIS (CBD &/OR THC) IN QLD AND ACT

Further to the recent announcement made on 10 January 2018, Medlab Clinical Limited (ASX: MDC) is pleased to announce that the Company has received confirmation from QLD and ACT Health Departments that Medlab's current Licence to Sell or Supply Schedule 8 or Schedule 9 Drugs allows Medlab to sell NanaBis™ in those respective territories.

"With the addition of QLD and ACT, Medlab is now permitted to sell NanaBis™ (cannabis-based medicine) in its primary core territories (NT and TAS currently excluded). With these new territories and the logistics program for distribution of the NanaBis™ progressing as planned, Medlab is well positioned to have NanaBis™ ready for commercialisation under the Government's Special Access Scheme at the end of February 2018" Sean Hall, Medlab CEO said.

ISSUED FOR: MEDLAB CLINICAL LTD (ASX: MDC) – www.medlab.co

FOR FURTHER INFORMATION: SEAN HALL, CEO, MEDLAB CLINICAL
TEL: +61 2 8203 9520, sean_hall@medlab.co

ISSUED BY: HILL + KNOWLTON STRATEGIES, MARCHA VAN DEN HEUVEL
TEL +61 2 9286 1226 OR +61 468 960 457, marcha.vandenheuvel@hkstrategies.com

ABOUT MEDLAB – www.medlab.co

Medlab Clinical is an Australian based medical life science company, developing therapeutic pathways for diagnosed chronic diseases. It is advanced in developing therapies for pain management, depression and obesity as well as earning revenue from sale of nutritional products in Australia and the United States. In pain management Medlab is developing cannabis-based medicines. The Medlab developed nano-particle medicine delivery system, Nanocelle™, is being applied to its medicines, nutritional products and off-patent drugs like statins. Medlab has a growing patent portfolio.